Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 8:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mycobacterium Clear all
Completed Phase 1 Interventional

A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3

NCT00000857
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
16
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 22, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

NCT02410772
View directory record Official record
Conditions
Tuberculosis
Interventions
rifapentine, rifapentine and moxifloxacin, control
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
12 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
San Francisco, California • New York, New York • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 22, 2026, 8:58 PM EDT
Terminated No phase listed Observational

Treatment Outcomes in Patient With Nontuberculous Mycobacterial Disease

NCT01680822
View directory record Official record
Conditions
Nontuberculous Mycobacterial Disease, Atypical Mycobacterium Infections
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 22, 2026, 8:58 PM EDT
Completed Phase 2 Interventional

A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

NCT00002170
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
San Diego, California • Torrance, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 22, 2026, 8:58 PM EDT
Recruiting Phase 2 Interventional

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

NCT07021794
View directory record Official record
Conditions
Post-COVID / Long-COVID
Interventions
Placebo, Sipavibart
Drug · Biological
Lead sponsor
Nancy Klimas
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 22, 2026, 8:58 PM EDT
Recruiting Phase 2 Interventional

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

NCT07284641
View directory record Official record
Conditions
Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome, STAT 1 Gain of Function, STAT 3 Gain of Function, Hypomorphic RAG1 Deficiency, CD40 Ligand Deficiency, Mendelian Susceptibility to Mycobacterial Disease, GATA2 Associated Immunodeficiency, CD40 Deficiency, Hypomorphic RAG2 Deficiency, Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome, Omenn Syndrome, Chronic Granulomatous Disease
Interventions
Hematopoietic stem cell transplant (HSCT)
Biological
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 22, 2026, 8:58 PM EDT
Completed Phase 1 Interventional

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

NCT00004736
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Nelfinavir mesylate, Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Lamivudine, Rifabutin, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2008 · Synced Sep 22, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

NCT03748992
View directory record Official record
Conditions
Nontuberculous Mycobacterium Infection
Interventions
gNO
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 22, 2026, 8:58 PM EDT
Completed No phase listed Observational

PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia

NCT04926922
View directory record Official record
Conditions
Tuberculosis, HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 22, 2026, 8:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Concordance Evaluation of T-SPOT®.TB Assay Performance (T-Cell SelectTM Study)

NCT04141982
View directory record Official record
Conditions
Tuberculosis
Interventions
T-Cell SelectTM Kit
Diagnostic Test
Lead sponsor
Oxford Immunotec
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Fall River, Massachusetts • Columbus, Ohio • Brownsville, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 22, 2026, 8:58 PM EDT
Completed No phase listed Observational

Healthcare-associated Links in Transmission of Nontuberculous Mycobacteria in Cystic Fibrosis

NCT04024423
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterium Infection
Interventions
Epidemiologic investigation
Other
Lead sponsor
National Jewish Health
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 22, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Results available

Trial of High-Dose Rifampin in Patients With TB

NCT01408914
View directory record Official record
Conditions
Tuberculosis
Interventions
Higher-Dose Rifampin
Drug
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 22, 2026, 8:58 PM EDT
Active, not recruiting Phase 2 Interventional

Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)

NCT02968212
View directory record Official record
Conditions
Mycobacterium Avium Complex
Interventions
Clofazimine, sugar pill
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Denver, Colorado • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 22, 2026, 8:58 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

NCT01200992
View directory record Official record
Conditions
Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
Interventions
EN3348, Mitomycin C
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 22, 2026, 8:58 PM EDT
Completed Phase 4 Interventional

TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB

NCT00023400
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Nelfinavir, Rifabutin
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
0 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2005 · Synced Sep 22, 2026, 8:58 PM EDT
Completed Not applicable Interventional

A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS

NCT00001995
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
Phoenix, Arizona • Harbor City, California • Irvine, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 22, 2026, 8:58 PM EDT
Completed No phase listed Observational Results available

Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection

NCT02687529
View directory record Official record
Conditions
Tuberculosis
Interventions
CST001
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 22, 2026, 8:58 PM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections

NCT00021567
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection
Interventions
Interferon Gamma for Aerosol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 22, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Latent TB Infection for Jailed Persons

NCT00128206
View directory record Official record
Conditions
Tuberculosis
Interventions
Isoniazid, Rifampin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 99 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 22, 2026, 8:58 PM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

NCT00001030
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 22, 2026, 8:58 PM EDT
Completed Early Phase 1 Interventional Results available

Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung

NCT05027958
View directory record Official record
Conditions
Healthy, Latent Tuberculosis Infection (LTBI)
Interventions
Tuberculin Purified Protein Derivative
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 22, 2026, 8:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Tuberculosis Volatile Organic Compounds

NCT01379066
View directory record Official record
Conditions
Pulmonary Tuberculosis
Interventions
Not listed
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
1 Year to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Oxnard, California • Ventura, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Sep 22, 2026, 8:58 PM EDT
Enrolling by invitation No phase listed Observational

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

NCT06262282
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
Interventions
mycobacteriophage
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 22, 2026, 8:58 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine

NCT00460759
View directory record Official record
Conditions
Mycobacterium Tuberculosis
Interventions
Moxifloxacin, Rifapentine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 22, 2026, 8:58 PM EDT